DSCAM-AS1 and metastatic malignant neoplasm in the lymph nodes: The higher the expression level of DSCAM-AS1, the lower the 5-year survival rate and the worse the prognosis In addition, DSCAM-AS1, AJCC stage, differentiation, lymph node metastasis, and PSA all have potential as prognostic markers for prostate cancer patients (Fig. 1e).